Chordoma Clinical Trial
Official title:
Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer
Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective:
Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study
Population Description: Existing NRSTS samples from the COG D9902/ARST0332 studies Sampling
Method: Non-Probability Sample
OBJECTIVES:
I. To determine the frequency with which actionable mutations are found in archived
non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor specimens using mass spectrometry
(MS) analysis of tumor-derived deoxyribonucleic acid (DNA).
OUTLINE:
Archived DNA tissue samples are analyzed for frequency of genetic mutations, including
single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), and small
deletions and/or insertions, by polymerase chain reaction (PCR) and mass spectometry
(Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations
correlate with patient or disease features such as tumor stage, histological grade, or
outcome.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03955042 -
Pemetrexed for the Treatment of Chordoma
|
Phase 1 | |
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Active, not recruiting |
NCT00496119 -
Proton Beam Therapy for Chordoma Patients
|
Phase 2 | |
| Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
| Completed |
NCT03595228 -
BN Brachyury and Radiation in Chordoma
|
Phase 2 | |
| Recruiting |
NCT06140732 -
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
|
Phase 2 | |
| Active, not recruiting |
NCT01175109 -
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
|
Phase 1 | |
| Completed |
NCT00150072 -
Efficacy and Safety of Imatinib in Chordoma
|
Phase 2 | |
| Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05041127 -
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
|
Phase 2 | |
| Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
| Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
| Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
| Recruiting |
NCT02986516 -
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
|
N/A | |
| Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
| Active, not recruiting |
NCT02989636 -
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
|
Phase 1 | |
| Active, not recruiting |
NCT03083678 -
Afatinib in Locally Advanced and Metastatic Chordoma
|
Phase 2 | |
| Completed |
NCT00713037 -
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
|
N/A | |
| Completed |
NCT00592748 -
Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
|
Phase 1/Phase 2 |